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Abstracts / Biol Blood Marrow Transplant 20 (2014) S45eS56 S47Methods: We identiﬁed 108 patients with resolved hepatitis
B infection (HB infection¼ HBcAb positive, HBsAg negative)
and 138 patients with normal HB serology (control) who
were matched for age, time of auto-HCT, disease status and
preparative regimen. Both groups received HDC + auto-HCT
between 1989 and 2012. Primary endpoints were: 1) HB viral
reactivation: HBsAg positivity or 10-fold increase in HB viral
DNA; 2) hepatotoxicity, as deﬁned in NCI CTCv3.0.
Results: There were no signiﬁcant differences in immuno-
globulin subtype, bone marrow plasmacytosis, serum beta-2
microglobulin, albumin, creatinine or lactic dehydrogenase
(LDH) between the HB infection or the control group.
Approximately 70% in each group received melphalan alone
as preparative regimen. In the HB infection group, 52
patients (48%) were HBsAb-positive, and 23 (21%) had
detectable HB viral DNA prior to auto-HCT. Serum HB viral
DNA level was<100 IU/m in 22 patients, and<300 IU/ml in 1
patient. HB e antigen (HBeAg) was non-reactive in all 4
patients evaluated prior to auto-HCT. Only 1 patient with HB
infection received pre-emptive antiviral therapy with Lam-
ivudine, while 4 patients received Lamivudine (3) or
Tenofovir (1) at reactivation for a median duration of 1 year.
HB viral reactivation was seen in 6 of 108 (5.6%) in the HB
infection group vs. 0 of 138 in the control group (p¼0.006).
There was a >10-fold increase in HB viral DNA in 5 of 6
patients with HB viral reactivation, and in 2 of 5 HBeAg also
became reactive. Median time to HB reactivation from auto-
HCT was 2.6 years. NCI CTCv3.0 grade 1, 2, 3 or 4 increase in
alanine transferase, aspartate transferase, total bilirubin or
alkaline phosphatase was seen in 6, 1, 2 and 3 patients,
respectively in the HB infection group (9.3%) vs. 1, 2, 0 and
1 (2.9%) patients in the control group (p¼ 0.049). Only one
patient (0.9%) in the HB infection group vs. 6 (4.3%) in control
group died of non-relapse causes within 1-year of auto-HCT
(p¼0.13).With a median follow up of 30 and 28months in HB
infection vs. control groups, the median PFS was 21.4 and
18.7 months, respectively (p¼0.66). Median OS in HB
infection and control groups was 57.0 vs. 65.2 months,
respectively (p¼0.93).
Conclusion: Resolved HB infection is associated with a
signiﬁcant risk of HB viral reactivation and hepatotoxicity in
patients undergoing auto-HCT for MM. These complications
were reversible and were not associated with an increase in
TRM, PFS or OS.
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Background: Lenalidomide (LEN) in combination with stan-
dard-dose melphalan has shown signiﬁcant anti-multiplemyeloma (MM) activity. In this phase I/II trial we evaluated
the safety and efﬁcacy of combining escalating doses of LEN
and high-dose melphalan (HDM) for patients undergoing
autologous hematopoietic stem cell transplantation (auto-
HCT) for relapsed MM.
Methods: Doses were chosen adaptively for successive co-
horts of size 3 using an extension of the safety-efﬁcacy trade-
off design.Each cohort received melphalan 200 mg/m2plus
LEN at one of the four dose levels orally, for 7 days. Primary
endpoints were dose-limiting toxicity (DLT), deﬁned as
regimen-related death, graft failure, grade 3 or 4 atrial
ﬁbrillation, grade 4 deep venous thrombosis, or pulmonary
embolism occurring within 30 days post auto-HCT, and
efﬁcacy, deﬁned as complete response (CR) at day +90.
Results: 57 patients were enrolled between March 2010 and
April 2013. After safely escalating to 100 mg of LEN, patients
were adaptively randomized among the 4 LEN dose levels.
Three, 5, 24 and 25 patients were treated at 25, 50, 75 or 100
mg respectively. Median age at auto-HCT was 60 (34-72)
years, and median time from diagnosis to auto-HCT was 33
(5-214) months, with no signiﬁcant differences between the
4 dose levels. Sixteen (28%) patients had high-risk abnor-
malities on conventional cytogenetic or ﬂuorescent in-situ
hybridization (FISH) studies. Median prior lines of treatment
were 3 (1-11). Eighteen patients (32%) had a prior auto-HCT.
Twenty-four (42%) patients received post auto-HCT mainte-
nance. DLT was not seen at any of the 4 dose levels prior to
adaptive randomization. Grade 3-4 non-hematologic toxicity
was seen in 40 (70%) patients, with no signiﬁcant differences
between the 4 dose levels. Two patients died of nonrelapse
causes (viral infection 1, cardiac failure 1) with a TRM of 3%.
Median time to both neutrophil and platelet engraftment
was 11 days. At day 90, 7 (12%) patients achieved a CR, 30
(53%) achieved CR or very good partial response (VGPR), and
51 (89.5%) achieved CR, VGPR or partial response (PR), with
no signiﬁcant differences in response rates among the 4 LEN
dose levels. With a median follow up of 10.5 months (range
0.5-33.4), median progression-free (PFS) and overall survival
(OS) have not yet been reached. One and 2-year PFSwere 63%
and 59%, respectively. One and 2-year OS were 82% and 72%,
respectively. These compare favorably with our previous
experience of 2-year PFS and OS of 24% and 59%, respectively,
after salvage auto-HCT with melphalan alone. No second
primary malignancy (SPM) has been seen so far.
Conclusion: LEN up to 100 mg daily x 7 days can be safely
combined with high-dose melphalan for relapsed myeloma.
The regimen is associated with a high overall response rate
and 2 year PFS and OS of 59% and 72% in relapsed and heavily
pretreated patients, with no SPM so far.
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Treatment of AL amyloidosis with high dose intravenous
melphalan and autologous stem cell transplant (HDM/SCT) is
effective in inducing hematologic and clinical remissions
associated with prolonged survival. We have performed 607
transplants from July 1994 to August 2013 in the Amyloidosis
Center at Boston Medical Center. Patients were enrolled in
several sequential IRBeapproved protocols.
